Autolus Therapeutics (AUTL) Competitors $2.52 -0.12 (-4.55%) Closing price 04:00 PM EasternExtended Trading$2.57 +0.05 (+1.98%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. RARE, ALVO, AMRX, MIRM, CPRX, ARWR, IBRX, OGN, APLS, and XENEShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Ultragenyx Pharmaceutical (RARE), Alvotech (ALVO), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Its Competitors Ultragenyx Pharmaceutical Alvotech Amneal Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals Arrowhead Pharmaceuticals ImmunityBio Organon & Co. Apellis Pharmaceuticals Xenon Pharmaceuticals Autolus Therapeutics (NASDAQ:AUTL) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends. Which has more volatility & risk, AUTL or RARE? Autolus Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Which has better earnings & valuation, AUTL or RARE? Autolus Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$9.01M74.43-$220.66M-$0.88-2.86Ultragenyx Pharmaceutical$590.69M4.38-$569.18M-$5.88-4.65 Do insiders and institutionals hold more shares of AUTL or RARE? 72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is AUTL or RARE more profitable? Autolus Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Autolus Therapeutics' return on equity of -52.82% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -52.82% -29.67% Ultragenyx Pharmaceutical -93.04%-186.49%-36.81% Do analysts prefer AUTL or RARE? Autolus Therapeutics currently has a consensus price target of $9.32, suggesting a potential upside of 269.84%. Ultragenyx Pharmaceutical has a consensus price target of $83.64, suggesting a potential upside of 205.94%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Autolus Therapeutics is more favorable than Ultragenyx Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Does the media refer more to AUTL or RARE? In the previous week, Autolus Therapeutics had 2 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 7 mentions for Autolus Therapeutics and 5 mentions for Ultragenyx Pharmaceutical. Autolus Therapeutics' average media sentiment score of 0.52 beat Ultragenyx Pharmaceutical's score of -0.21 indicating that Autolus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryAutolus Therapeutics beats Ultragenyx Pharmaceutical on 13 of the 16 factors compared between the two stocks. Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$670.68M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-2.8621.1828.1120.03Price / Sales74.43337.65460.63103.88Price / CashN/A43.2336.5559.01Price / Book1.578.368.655.90Net Income-$220.66M-$55.19M$3.25B$258.66M7 Day Performance4.56%5.89%4.20%2.23%1 Month Performance8.62%17.63%10.83%12.77%1 Year Performance-45.22%5.10%34.67%19.36% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.6099 of 5 stars$2.52-4.5%$9.32+269.8%-38.5%$670.68M$9.01M-2.86330RAREUltragenyx Pharmaceutical4.35 of 5 stars$29.23-0.9%$83.64+186.2%-39.5%$2.76B$560.23M-4.971,294Upcoming EarningsHigh Trading VolumeALVOAlvotech2.8352 of 5 stars$8.90+4.5%$18.00+102.2%-21.0%$2.68B$585.60M24.051,032AMRXAmneal Pharmaceuticals3.1369 of 5 stars$8.42+1.1%$11.60+37.8%+8.0%$2.64B$2.79B-210.458,100MIRMMirum Pharmaceuticals3.8597 of 5 stars$53.28+1.2%$65.50+22.9%+33.5%$2.64B$336.89M-33.09140CPRXCatalyst Pharmaceuticals4.9202 of 5 stars$21.62-0.9%$32.83+51.9%+20.0%$2.64B$491.73M13.7780News CoveragePositive NewsAnalyst RevisionARWRArrowhead Pharmaceuticals3.782 of 5 stars$18.61+1.6%$43.71+134.9%-43.8%$2.57B$545.21M-13.29400News CoveragePositive NewsIBRXImmunityBio2.1313 of 5 stars$2.90+3.2%$12.25+322.4%-43.5%$2.56B$31.22M-5.00590News CoverageAnalyst ForecastOGNOrganon & Co.4.7689 of 5 stars$9.83-1.2%$18.00+83.2%-53.5%$2.55B$6.40B3.414,000APLSApellis Pharmaceuticals4.2398 of 5 stars$19.91+2.4%$39.79+99.8%-46.3%$2.50B$781.37M-11.12770Upcoming EarningsXENEXenon Pharmaceuticals3.7513 of 5 stars$32.60+1.2%$54.82+68.2%-29.1%$2.50B$9.43M-10.09210Positive NewsOptions Volume Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Competitors Alvotech Competitors Amneal Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors ImmunityBio Competitors Organon & Co. Competitors Apellis Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUTL Stock Alerts